CN103768114B - A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared - Google Patents
A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared Download PDFInfo
- Publication number
- CN103768114B CN103768114B CN201210405870.8A CN201210405870A CN103768114B CN 103768114 B CN103768114 B CN 103768114B CN 201210405870 A CN201210405870 A CN 201210405870A CN 103768114 B CN103768114 B CN 103768114B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- medicine
- wilsonii
- herba hyperici
- cerebral apoplexy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared, wherein pharmaceutical composition is made up of Herba Hyperici Monogyni and wilsonii, various formulations can be made with pharmaceutically acceptable carrier or excipient.Pharmacological research shows that the pharmaceutical composition is obviously improved to the animal survival time after global cerebral ischemia, significantly reduces the ischemic areas of post-stroke, has protective effect to nervous function, has the function that to prevent or treat cerebral apoplexy.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of pharmaceutical composition treats or prevents the medicine of cerebral apoplexy preparing
In application.
Background technology
Cerebral apoplexy be acute generation blood vessel or blood flow anomalies caused by brain blood circulation disorder and cause neurologic impairment
Syndrome, there is the characteristics of high incidence, high disability rate, high relapse rate and high fatal rate, be to be only second to cardiovascular disease and cancer
The third-largest " killer ", have become the principal disease for threatening human health and life.Also, as the whole world is to aging society
Into the continuous quickening of paces, the incidence of disease of cerebral apoplexy is still further riseing, in view of the significant damage of cerebral apoplexy, exploitation reduces
Stroke Death rate, patient's functional rehabilitation, the medicine for the treatment cerebral apoplexy for improving patients ' life quality is promoted to have become the whole world
One of study hotspot of medical personal.
Ischemic cerebral apoplexy refers to because brain blood supplies obstacle, the ischemic of limitation brain tissue caused by ischemic, anoxic
Property necrosis or cerebromalacia, pathophysiological process it is extremely complex, affected by many factors, wherein energy metabolism impairment, excitability ammonia
The mechanism such as base toxic effect of acid, inflammatory reaction, Penumbra zone depolarising and Apoptosis take part in its pathophysiological process jointly.Mesh
The preceding treatment to cerebral arterial thrombosis, mainly angularly enter from neuroprotection, anti-freezing, thrombolysis, increase CBF and hypotensive
OK, conventional cerebral apoplexy chemotherapeutic agent includes：1）Thrombolysis class medicine, 2）Antiplatelet drug, 3）Anticoagulant, 4）Nerve
Cell-protecting medicines etc..But these medicine majorities can only all be directed to being extenuated and/or being treated in a certain respect for cerebral apoplexy, treat
Act on single, effect is undesirable, and many adverse reactions be present.For example, conventional thromboembolism treatment drug entities fibrin
Dissolved preferment activator（tPA）Although can rapid thrombus, can not improve due to neuron caused by ischemic by
Damage, and destruction blood-CSF barrier, increase bleeding risk, aggravation excititoxic etc. be present seriously not in its continuous is reported
Good reaction [yellow meaningful ripple etc., neuroprotection and cerebral arterial thrombosis treatment, translational medicine research（Electronic edition）2012,2（1）：40-
53], above mentioned problem is also thrombolysis class medicine in Clinical practice the defects of generally existing.
In addition, Chinese medicine preparation also makes some progress in terms of cerebral apoplexy is treated, such as common having improves the heart
The gingko leaf preparation of Cerebrovascular disorders effect, there is definite work for treatment acute ischemic cerebral apoplexy by many research reports
With.But providing that the total flavonoids content of ginkgo biloba p.e must not be less than 24.0% in 2010 editions pharmacopeia, terpene lactone contains
Must not measure less than 6.0%, ginkgo acid content must not exceed 10%, and total flavonoids content and terpene lactone in ginkgo leaf medicinal material
Content is only respectively 0.4% and 0.25%.Therefore, in gingko leaf preparation the high standard of corresponding active component content necessarily to its former material
Quality, quantity, the extraction process of material have higher requirements, so as to cause higher production cost, in addition, ginkgo biloba p.e exists
Easily occurring a variety of adverse reactions such as bleeding, hypertension induced, allergy on Clinical practice, [Wang Yuhui etc., ginkgo biloba p.e is not
Good reaction, 2001,3:184-186].In addition, also disclose that some are other in the Chinese patent such as CN1686299, CN10197242
The Traditional Chinese medicine composition of cerebral apoplexy is treated, but its prescription is complicated, and production cost is high, and Drug's control difficulty is big, is unfavorable for
Industrialized production.Therefore, seek a kind of prescription is simple, curative for effect, security is good, beneficial to industrialized production treatment brain soldier
In Chinese medicine tool be of great significance.
Herba Hyperici Monogyni, is called St. john's wort, Guttiferae Hypericum herbaceos perennial, be distributed in the world it is most wide
Natural plants, the ground such as Hubei, Sichuan, Guizhou, Gansu, Shanxi, Jiangxi, Jiangsu, Shandong are distributed mainly in China.Pass through Ye Jin
Silk peach clinical practice in addition to the effect of traditional calmness, anti-inflammatory, wound healing etc., be also reported available for depression,
The treatment of the disease such as A type and hepatitis B, AIDS, tumour.2006 again studies have reported that hyperforine is for brain soldier
In after neurotrosis there is protective effect [Kumar V, Mdzinarishvili A, Kiewert C, et al.NMDA
receptor-antagonistic properties of hyperforin,a constituent of St.John's
Wort.J Pharmacol Sci.2006,102(1):47-54].In addition, the larger scale clinical research hair of Herba Hyperici Monogyni preparation
It is existing, although it is in use in the presence of some side effects, such as GI irritation (0.6%), allergic reaction (0.5%), fatigue
(0.4%) etc., but these side reactions be it is slight, temporary transient, and relative harmless [Yang get Po etc., foreign countries are to the anti-suppression of hypericum perforatum
The clinical verification of strongly fragrant curative effect, Journal of Chinese Integrative Medicine, 2004,2（3）：231-234].
Wilsonii be Araliaceae root, rhizome and stem, also known as slender acanthopanax ginseng, sting bent stick, be mainly distributed on China northeast,
North China, and the ground such as Korea, Japan and Russia.Wilsonii is widely used, is with a long history, and modern pharmacology research shows
It has many effects such as neuro-protective, immunological regulation, anti-aging, is clinically widely used.The research that week is waited by the emperor himself
Report and use Chi-Wu-Jia Injection in Treating cerebral arterial thrombosis, the results showed that Chi-Wu-Jia Injection in Treating group is suffered from for cerebral apoplexy
The therapeutic effect of person is substantially better than control group [the Chi-Wu-Jia Injection in Treating ischemic brains of admiring in week without using Radix Et Caulis Acanthopanacis Senticosi injection
228 clinical analysis of palsy, Guangxi medical science, 2006,28 (9):1396-1397].And the long term toxicity research of Radix Et Caulis Acanthopanacis Senticosi injection
Show its high and low dose group and physiological saline（Blank）Control group compares, during successive administration 28d, to organ coefficient, animal
The indices such as hematological indices, biochemical indicator have no significant effect；Each group animal is in diet, activity, excretion, spirit after drug withdrawal
State etc. is showed no notable difference；Without specifically sexually revising after drug withdrawal without slowness toxicity [Song Yan occurs for histopathologic slide
Spring etc., research of the Radix Et Caulis Acanthopanacis Senticosi injection to rat chronic toxicity test, drug evaluation research, 2010,33 (1):1-4].
Herba Hyperici Monogyni is respectively provided with widely distributed, raw material with wilsonii and is easy to get, and action target spot is more, and it is excellent that toxic side effect is small etc.
Point.Capsule for reliving liver and reliving upset is the Chinese medicine composition with Herba Hyperici Monogyni and wilsonii prescription, for treating light, moderate unipolar depression
Disease, it is the Chinese patent drug for being used to treat depression of domestic first SFDA approvals, treatment depression works well, and correlative study shows it
Adverse events incidence is small over the course for the treatment of, and without the generation of serious and severe adverse events, [Sun Xinyu etc., capsule for reliving liver and reliving upset is controlled
Treat the randomized double-blind placebo-controlled study of light moderate depressive patients, Chinese Journal ofNew Drugs, 2009,18
（5）：413-416].
Have no at present and Herba Hyperici Monogyni and wilsonii are applied to treatment cerebral apoplexy jointly, and obtain curative for effect, safety
The report of the good medicine of property.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition containing Herba Hyperici Monogyni and wilsonii prepare treatment or
The percentage by weight of application in preventing brain stroke medicine, Herba Hyperici Monogyni and wilsonii is：Herba Hyperici Monogyni 35-65%, thorn five
Add 65-35%；Preferable percentage by weight is Herba Hyperici Monogyni 50-65%, wilsonii 50-35%；Preferred percentage by weight is
Herba Hyperici Monogyni 54.5%, wilsonii 45.5%.
Described cerebral apoplexy is preferably cerebral arterial thrombosis.
Pharmaceutical preparation can be made with pharmaceutically acceptable carrier or excipient in pharmaceutical composition provided by the invention, the system
Agent can be traditional oral preparation, such as capsule, tablet, granule etc..
The present invention investigates medicine using bilateral common carotid arteries and the acute cerebral ischemia mouse model of vagus nerve caused by ligature
The effect of composition, described mouse model modeling method are：The 0.5h after mouse last time gastric infusion, with ether to it
It is rapid to ligature bilateral common carotid arteries and vagus nerve after carrying out superficial anesthesia, observe the mouse survival time.The animal model is anxious
Property cerebral hypoxia ischemia common model, and acute cerebral ischemia anoxic is exactly one of pathological effect of cerebral arterial thrombosis, therefore, should
Time-to-live after animal model administration can tentatively reflect protective effect of the medicine to cerebral ischemia, anoxic, can be used as and lack
The screening index of courageous and upright cerebral apoplexy medicine.Test result indicates that heretofore described pharmaceutical composition is to bilateral ligation
Mouse is caused to lack time-to-live significantly extension compared with model group after acute cerebral ischemia, with wilsonii is used alone or passes through leaf spun gold
It is obvious to illustrate that the pharmaceutical composition acts on for cerebral ischemia, hypoxia protection compared to being also obviously prolonged for peach group, and with significant
Synergy.
Middle cerebral artery occlusion model is acknowledged as the focal cerebral infarction animal model of standard, is moved wherein in line brush brain
Arteries and veins cerebral ischemic model is preferred modeling method [the line brush rats after transient focal cerebral ischemia model for studying ischemic brain damage animal model
Improvement and evaluation, Central-South medical science magazine, 2012,40 (3):291-294].Therefore the present invention is using caused by line brush
Rat brain stroke model further study by the prevention to pharmaceutical composition or the effect for the treatment of cerebral apoplexy and dosage, described line
Bolt method modeling method is：The 1h after rat last time gastric infusion, fiber crops are injected intraperitoneally with 10% yellow Jackets (30mg/kg)
It is liquor-saturated, fixation of lying on the back, neck median incision, separate and expose left common carotid and the inside and outside artery of neck, ligature arteria carotis communis and neck
Outer artery proximal part, an osculum is opened in arteria carotis communis distal end（Outside neck, internal carotid crotch about 5mm）, insert MACO
Bolt 2.0 ± 0.2cm of line, stops when feeling to have light resistance, tightens and fixes plug wire, skin suture, after blocking blood flow 2h, pulls out line
Reperfu- sion is realized, rat is put to death in cerebral ischemia re-pouring 48h, and neurological deficits score is carried out before putting to death；Taken after sacrificed by decapitation
Brain section observes rat cerebral ischemia volume.Neuromotor function defect appraisal result after rat model administration shows the medicine group
Each dosage group of compound can significantly improve the neuromotor function of cerebral arterial thrombosis rat, and its ischemic volume result of study is shown
Each dosage group of the pharmaceutical composition can significantly reduce brain tissue death domain and volume caused by ischemia-reperfusion.
The extraction preparation method of pharmaceutical composition provided by the invention is：Herba Hyperici Monogyni medicinal material is added into 70% alcohol reflux
Extraction 2 times, 1 hour every time, merge extract solution, filtration, ethanol is recovered under reduced pressure, is concentrated into the leaching of relative density about 1.10 (70 DEG C)
Cream, dry extract is spray-dried to obtain, obtains extract of hypericum perforatum；By wilsonii pulverizing medicinal materials into fragment, 3 are added water to cook
It is secondary, 2 hours every time, collecting decoction, filter, filtrate is concentrated into the medicinal extract of relative density about 1.18 (70 DEG C), and being spray-dried to do
Extract powder, obtain siberian Ginseng P.E；Above two extract is taken, uniformly mixes and produces pharmaceutical composition.The extracting method institute
Need equipment, reagent simple, easy to operate, production cost is relatively low.
The present invention compared with prior art, has advantages below：
1st, in pharmaceutical composition provided by the invention during cerebral apoplexy is treated or prevented, due to Herba Hyperici Monogyni and thorn
The synergy of slender acanthopanax, the pharmaceutical composition is to the time-to-live after bilateral ligation cause mouse ischemic and exclusive use
Wilsonii or Herba Hyperici Monogyni group, which are compared, has notable extension to act on；And the pharmaceutical composition is transported for the nerve of post-stroke
Damage after dynamic function, ischemia-reperfusion and have significant therapeutic effect, therapeutic effect is definite.
2nd, chemicals toxic side effect of the prior art is larger, and the present invention pharmaceutical composition in wilsonii and pass through
The xicity related research of leaf Hypericum Chinense shows the two small toxicity, and adverse reaction occurs less, safe.
3rd, there is extraction process or formulation ingredients complexity, production cost height, quality control in Chinese medicine preparation of the prior art
The problems such as difficulty is big, and the pharmaceutical composition in the present invention is only made up of two taste medicines, prescription is simple, is easier to quality control, and
Extracting method is simple, and production cost is lower, is adapted to large-scale production.
Brief description of the drawings
Fig. 1 is the rat whole brain slice map of each experimental group in embodiment two, wherein 1 is negative control group in embodiment two
（Normal rat）Whole br ain slices, 2 be cerebral apoplexy blank control group in embodiment two（Rat model）Whole br ain slices, 3 be embodiment
Two positives control groups（Cerebral apoplexy rat model is treated through Folium Ginkgo）Whole br ain slices, 4 be pharmaceutical composition in embodiment two
Low dose group whole br ain slices, 5 be pharmaceutical composition high dose group whole br ain slices in embodiment two
Embodiment
Following examples are that the present invention is explained further, it is impossible to are limited the scope of the invention.
The pharmaceutical composition of embodiment 1 is to the mouse survival time after ligation bilateral common carotid arteries and vagus nerve cause cerebral ischemia
Influence
1. experiment material
Experimental animal：Kunming mice（KM mouse）, lot number SCXK（River）2004-15, provided by Sichuan Academy of Medical Sciences；
Experimental drug：Folium Ginkgo（Tanakan）, specification 40mg/ pieces, product batch number C02191, manufacturer be Bo Fu-
Yi Pusheng industrial groups（France）；Extractum Acanthopanacis Senticosi powder, lot number 110302, Herba Hyperici Monogyni extract powder, lot number 110303 by
Chengdu Kanghong Medicine Group Co.ltd provides；
Experiment reagent：Ether（Analyze pure, Tianjin Fu Yu Fine Chemical Co., Ltd）
Operating theater instruments：Operating scissors, haemostatic clamp, needle forceps.
2. experimental method
Experiment packet：
Kunming mice 108 is taken, male and female half and half, following 9 groups are divided into according to body weight and sex：
Negative control group：It is given only the distilled water that gained volume is calculated by 10ml/kg mouse weights.
Positive controls：Give Tanakan 20mg/kg.
Wilsonii group：Give siberian Ginseng P.E 480mg/kg.
Herba Hyperici Monogyni group：Give extract of hypericum perforatum 480mg/kg.
Pharmaceutical composition 1：Herba Hyperici Monogyni:Wilsonii=35:65（Percentage by weight）Pharmaceutical composition, by 480mg/
Kg is administered.
Pharmaceutical composition 2：Herba Hyperici Monogyni:Wilsonii=50:50（Percentage by weight）Pharmaceutical composition, by 480mg/
Kg is administered.
Pharmaceutical composition 3：Herba Hyperici Monogyni:Wilsonii=54.5:45.5（Percentage by weight）Pharmaceutical composition, press
480mg/kg is administered.
Pharmaceutical composition 4：Herba Hyperici Monogyni:Wilsonii=62:38（Percentage by weight）Pharmaceutical composition, by 480mg/
Kg is administered.
Pharmaceutical composition 5：Herba Hyperici Monogyni:Wilsonii=65:35（Percentage by weight）Pharmaceutical composition, by 480mg/
Kg is administered.
Drug solution is prepared：Medicine by more than in each experimental group or each component in pharmaceutical composition are according to weight proportion
And after mouse weight calculates total dosage, solution is configured to by solvent of distilled water, solvent volume is that 10ml/kg is small
Mouse body weight.
According to above-mentioned experiment packet and each group drug solution volume, gastric infusion is carried out to mouse, it is 2 times a day, continuous to fill
Stomach is administered 7 times.The 0.5h after last gavage, mouse is anaesthetized with ether superficial, it is rapid to ligature bilateral common carotid arteries and be confused absent-minded
Through observing and recording the mouse survival time of each group（s）, the results are shown in Table 1.
3. experimental result
Shadow of the pharmaceutical composition of table 1 to the time-to-live after cerebral ischemia caused by ligation mouse bilateral common carotid arteries and vagus nerve
Ring
Compared with model control group, * P ＜ 0.05
Upper table result shows, compared with negative control group, pharmaceutical composition 1-5 can be obviously prolonged the survival of model mice
Time, illustrate that the pharmaceutical composition has preferable protective effect for cerebral ischemia, anoxic.Pharmaceutical composition 1-5 is administered and thorn five
Add or time-to-live that Herba Hyperici Monogyni is administered alone compared to model mice substantially increases, illustrate wilsonii in the pharmaceutical composition
Obvious synergy between Herba Hyperici Monogyni be present.Comparative drug composition 1-5 is learnt to the time-to-live of model mice
When the weight proportion in pharmaceutical composition is Herba Hyperici Monogyni：35-65%, wilsonii：During 65-35%, each composition can be effective
Extend the mouse survival time；When weight proportion is Herba Hyperici Monogyni：50-65%, wilsonii：During 65-50%（Pharmaceutical composition 2-
5）, the prolonged survival period of mouse is more notable；When weight proportion is Herba Hyperici Monogyni：54.55%, wilsonii：When 45.45%
（Pharmaceutical composition 3）, mouse survival time lengthening is the most notable, its time-to-live and negative control group, wilsonii group and passes through leaf
Section Ascyreia is compared and is improved largely, and, the drug regimen proportioning under suitable with positive control medicine group action effect
Thing is best to focal cerebral ischemia protective effect.
The pharmaceutical composition of embodiment 2 causes the neurologic score and ischemic volume of Focal Cerebral Ischemia-Reperfusion in Rats to line brush
Influence
1. experiment material
Experimental animal：SD rats, lot number SCXK（River）2004-15, provided by Sichuan Academy of Medical Sciences；
Experimental drug：Folium Ginkgo（Tanakan）, specification 40mg/ pieces, product batch number C02191, manufacturer be Bo Fu-
Yi Pusheng industrial groups（France）；Extractum Acanthopanacis Senticosi powder, lot number 110302, Herba Hyperici Monogyni extract powder, lot number 110303 by
Chengdu Kanghong Medicine Group Co.ltd provides；
Experiment reagent：2,3, 5-Triphenyltertrazoliumchloride (TTC), lot number BCBH1872V, produce company Sigma；Penta bar
Than appropriate sodium（25g/ bottles）, lot number：061222, Beijing chemical reagents corporation；
Laboratory apparatus：Electro-heating standing-temperature cultivator, model：DNP-9082, the upper grand experimental facilities Co., Ltd of Nereid；Cold light hand
Art shadowless lamp, model：KL04L, section insult doctor's electricity；Canon's camera, model：EOS1100；Rat cerebral ischemia（MCAO）Line bolt, model：
2636-100,2838-100, Shadong Biological Technology Co., Ltd., Beijing.
Operating theater instruments：Operating scissors, haemostatic clamp, needle forceps, artery clamp.
2. experimental method
Experiment packet：
Healthy male SD rat 80,180~220g of body weight is taken, is divided into following 5 groups by weight average：
Negative control group：Healthy male SD rat, it is given only the distillation that gained volume is calculated by 10ml/kg rat body weights
Water.
Blank control group：Rat after line brush modeling, it is given only the distillation that gained volume is calculated by 10ml/kg rat body weights
Water.
Positive controls：Rat after line brush modeling, give Tanakan 20mg/kg.
Pharmaceutical composition low dose group：Herba Hyperici Monogyni:Wilsonii=54.5:45.5（Percentage by weight）Drug regimen
Thing, it is administered by 120mg/kg.
Pharmaceutical composition high dose group：Herba Hyperici Monogyni:Wilsonii=54.5:45.5（Percentage by weight）Drug regimen
Thing, it is administered by 240mg/kg.
Drug solution is prepared：Medicine by more than in each experimental group or each component in pharmaceutical composition are according to ratio and greatly
After mouse body weight calculates total dosage, solution is configured to by solvent of distilled water, solvent volume is 10ml/kg rat bodies
Weight.
According to above-mentioned experiment packet and each group drug solution volume, gastric infusion is carried out to mouse, it is one time a day, continuous to fill
Stomach is administered 30 days.The 1h after last gavage, by rat with 10% yellow Jackets (30mg/kg) intraperitoneal injection of anesthesia, lie on the back solid
Fixed, neck median incision, is separated and exposure left common carotid and the inside and outside artery of neck, ligation arteria carotis communis and external carotid artery are near
Heart end, an osculum is opened in arteria carotis communis distal end（Outside neck, internal carotid crotch about 5mm）, insertion MACO bolts line 2.0 ±
0.2cm, stop when feeling to have light resistance, tighten and fixed plug wire, skin suture, after blocking blood flow 2h, pull out line and realize and fill again
Note, put to death after 48h.
Neurological deficits score is carried out to rat before execution, specific standards of grading are with reference to the third edition《Pharmacological evaluation side
The science of law》In standards of grading carry out：1. putting forward rat-tail observation forelimb flexing situation, such as double forelimbs symmetrically stretch to ground, are designated as 0 point,
Offside forelimb such as operation occurs that wrist is bent, elbow flexing, shoulder inward turning or existing wrist elbow flexing have shoulder inward turning person again, be calculated as 1 respectively, 2,
3rd, 4 points.2. animal is placed in ground grading, both shoulders are pushed away respectively and are moved to bilateral, check resistance, such as bilateral resistance is reciprocity and has
Power, is calculated as 0 point, drop in resistance person when such as being promoted to the offside of operation, according to decline degree difference be divided into it is light, in, weigh three degree, point
1,2,3 point is not calculated as.3. the double forelimbs of animal are put on a wire netting, the Muscle tensility of double forelimbs is observed.The Muscle tensility pair of double forelimbs
Deng and strong person be calculated as 0 point, declining degree difference also according to operation offside limb tension force is calculated as 1,2,3 point.Do not stop 4. animal has
To the side person of turn-taking, 1 point is calculated as.According to standards of grading, full marks are 11 points, and fraction is higher, and the neurological dysfunction of animal is tighter
Weight.Each group neurological deficits score result is as shown in table 2.
The sacrificed by decapitation rat at the end of experiment, takes out rapidly brain, quick-frozen 15min or so in -20 DEG C of refrigerators, takes hat
The thick whole br ain slices of 2mm are uniformly cut into shape face, are put into rapidly in 2%TTC solution, 15min are incubated in 37 DEG C of lucifuges, therebetween every 4
~5min is stirred once, whole br ain slices is carried out stain incubation uniformly in contact with to dye liquor, and the whole br ain slices being incubated are taken out,
Digital camera amplifies 1.5 times and taken pictures, and each group Part of photos taken is as shown in Figure 1.Photo is inputted into computer, using imageplus6.0
Software calculates its infarct size, each whole br ain slices Infarction volume（2mm is multiplied by equal to infarct size）Sum is total Infarction volume,
Total Infarction volume and the ratio of brain cumulative volume are cerebral ischemia volume.Each experimental group cerebral ischemia volume result is as shown in table 3.3.
Experimental result
The cerebral arterial thrombosis rat motor function scores result of table 2
Compared with model control group, * P ＜ 0.05, * * P ＜ 0.01
The result of table 2 shows, two pharmaceutical composition groups and model group（Blank control group）Compare, neuromotor function scoring
Significantly reduce, show that the pharmaceutical composition is significantly improved to the neurological dysfunction of animal pattern.And low dosage medicine
The appraisal result of compositions is suitable with the medicine Tanakan action effect that positive controls use, high dose medicament composition
Appraisal result is lower than Tanakan, illustrates the pharmaceutical composition in the nerve fortune for improving neurological dysfunction, promoting post-stroke
It is suitable with the tablets of Ginkgo biloba L effect that purity is higher or more preferably in terms of dynamic functional rehabilitation.
The cerebral arterial thrombosis rat cerebral ischemia volume result of table 3
Compared with model control group, * * P ＜ 0.01
Fig. 1 is observed, it is apparent that normal rat whole br ain slices are in rose, and the rat whole brain for infarct occur is cut
Piece portion of tissue shows white, and boundary line is more clearly demarcated, wherein normal rat whole br ain slices whole br ain slices（No. 1 in accompanying drawing 1）
It is in rose, cerebral apoplexy rat model whole br ain slices（No. 2 in accompanying drawing 1）It is large area infarct that large area white, which is presented,
And the brain sections after Tanakan, pharmaceutical composition high dose, low dose therapy（3,4, No. 5 in accompanying drawing 1）Rose
Obvious increase, pale infarct region significantly reduces.
The cerebral ischemia volume result being calculated in table 3 shows, two pharmaceutical composition groups and model group（Blank control
Group）Compare, can pole substantially reduce rat infarcted region volume, improve cerebral ischemia.The infarcted region of low dose pharmaceutical compositions
Volume is suitable with the medicine Tanakan that positive controls use, and the infarcted region of high dose medicament composition is smaller than Tanakan,
Illustrate the pharmaceutical composition improve post-stroke ischemic injuries in terms of it is suitable with the tablets of Ginkgo biloba L effect that purity is higher or
Person is more preferable.
The preparation of the pharmaceutical composition of embodiment 3
Pharmaceutical composition 1：Herba Hyperici Monogyni 1800g wilsoniis 1500g
Pharmaceutical composition 2：Herba Hyperici Monogyni 1155g wilsoniis 2145g
Pharmaceutical composition 3：Herba Hyperici Monogyni 2145g wilsoniis 1155g
Pharmaceutical composition 4：Herba Hyperici Monogyni 1650g wilsoniis 1650g
Pharmaceutical composition 5：Herba Hyperici Monogyni 2046g wilsoniis 1254g
Each pharmaceutical composition preparation method：70% alcohol reflux is added to extract 2 times the Herba Hyperici Monogyni medicinal material of the dosage,
1 hour every time, merge extract solution, filtration, ethanol is recovered under reduced pressure, is concentrated into the medicinal extract of relative density about 1.10 (70 DEG C), spray
Dry dry extract, obtains extract of hypericum perforatum；By the wilsonii pulverizing medicinal materials of the dosage into fragment, add water to cook
3 times, 2 hours every time, collecting decoction, filter, filtrate is concentrated into the medicinal extract of relative density about 1.18 (70 DEG C), and being spray-dried to do
Extract powder, obtain siberian Ginseng P.E；Above two extract is taken, uniformly mixes and produces pharmaceutical composition.
The preparation of the medicament composition capsule agent of embodiment 4
After the pharmaceutical composition being prepared according to preparation method in embodiment 3 is crossed into 40 mesh sieves, pregelatinized starch is added
Its weight is reached 340g, add talcum powder 18g, magnesium stearate 2g is well mixed, and is loaded capsule, is made 1000.
The preparation of the medicinal composition tablets of embodiment 5
After the pharmaceutical composition being prepared according to preparation method in embodiment 3 is crossed into 40 mesh sieves, adding lactose makes its heavy
Amount reaches 408g, adds starch 50g, hydroxypropylcellulose 40g, is well mixed, and with 75% alcohol granulation, dries, whole grain, adds
2g magnesium stearates are well mixed, tabletting, are made 1000.
The preparation of the medicament composition granule agent of embodiment 6
After the pharmaceutical composition being prepared according to preparation method in embodiment 3 is crossed into 40 mesh sieves, adding lactose makes its heavy
Amount reaches 630g, and mannitol 70g is well mixed, and with 75% alcohol granulation, dries, whole grain, is made 450 bags.
Claims (2)
- A kind of 1. work of purposes, wherein described pharmaceutical composition of pharmaceutical composition in prevention or treatment cerebral apoplexy medicine is prepared Property composition is prepared by Herba Hyperici Monogyni and wilsonii, and the percentage by weight of wherein Herba Hyperici Monogyni and wilsonii is：Pass through Leaf Hypericum Chinense 54.5%, wilsonii 45.5%.
- 2. purposes according to claim 1, it is characterised in that the cerebral apoplexy is cerebral arterial thrombosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210405870.8A CN103768114B (en) | 2012-10-23 | 2012-10-23 | A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210405870.8A CN103768114B (en) | 2012-10-23 | 2012-10-23 | A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103768114A CN103768114A (en) | 2014-05-07 |
| CN103768114B true CN103768114B (en) | 2017-12-19 |
Family
ID=50561174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210405870.8A Active CN103768114B (en) | 2012-10-23 | 2012-10-23 | A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768114B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524595A (en) * | 2018-06-21 | 2018-09-14 | 南方医科大学 | Chinese medicine composition is preparing the application in treating cerebral apoplexy drug |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381242A (en) * | 2001-04-16 | 2002-11-27 | 成都康弘制药有限公司 | Capsule for treating depression |
-
2012
- 2012-10-23 CN CN201210405870.8A patent/CN103768114B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381242A (en) * | 2001-04-16 | 2002-11-27 | 成都康弘制药有限公司 | Capsule for treating depression |
Non-Patent Citations (3)
| Title |
|---|
| 刺五加注射液治疗缺血性脑卒中228例临床分析;周钦;《广西医学》;20060930;第28卷(第9期);第1396-1397页 * |
| 圣约翰草提取物的临床研究进展;王泽剑等;《国外医学脑血管疾病分册》;20050531;第11卷(第3期);第212-214页 * |
| 舒肝解郁胶囊治疗脑卒中后抑郁症50例临床观察;朱继人等;《中国实用神经疾病杂志》;20111231;第88页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103768114A (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8597695B1 (en) | Herbal combinations for treatment of a skin condition | |
| EP3076984B1 (en) | Herbal combinations for treatment of a skin condition | |
| CN100404035C (en) | Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease | |
| US10780141B2 (en) | Herbal combinations for treating eczema | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| US20160136218A1 (en) | Molecular and Herbal Combinations for Disease Therapy | |
| CN116019824B (en) | Traditional Chinese medicine composition for preventing and treating microcirculation disturbance | |
| US20170049687A1 (en) | Herbal Combinations For Treating Scalp Conditions | |
| CN101890062B (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN103768114B (en) | A kind of application of pharmaceutical composition in the medicine for treating or preventing cerebral apoplexy is prepared | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| WO2002092109A1 (en) | Herbal composition and its use | |
| CN102048824B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease and application thereof | |
| US20160375076A1 (en) | Herbal Combinations for Treating Eczema | |
| CN106421293A (en) | Traditional Chinese medicine effective part composition for treating cardiovascular and cerebrovascular diseases | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN105796764A (en) | Preparation method and purpose of negundo chastetree fruit total lignans | |
| CN1321649C (en) | Composition for treating female algomenorrhea and its preparing method | |
| CN1246016C (en) | Compound formulation of traditional Chinese medicine for climacteric syndrome and preparation method | |
| CN115252742B (en) | A Chinese medicinal oral preparation for treating traumatic injury and fracture | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN113041254B (en) | Chinese medicinal composition comprising herba Goodyearae Repentis and its preparation method | |
| CN105878721A (en) | Traditional Chinese medicine formula taken before drinking and capable of reducing concentration of alcohol in human body after drinking, protective liver and nourishing stomach | |
| CN110237110A (en) | A kind of acanthopanax senticosus extract and its extracting method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201111 Address after: Pengzhou City, Chengdu City, Sichuan province 611930 days Peng Zhen Hua Long Road No. 89 Patentee after: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Address before: 610036 Jinniu District, Sichuan, Sichuan West Road, No. 36, No. Patentee before: CHENGDU KANGHONG PHARMACEUTICAL GROUP Co.,Ltd. |